208 related articles for article (PubMed ID: 25179843)
1. Novel mutations and role of the LKB1 gene as a tumor suppressor in renal cell carcinoma.
Yalniz Z; Tigli H; Tigli H; Sanli O; Dalay N; Buyru N
Tumour Biol; 2014 Dec; 35(12):12361-8. PubMed ID: 25179843
[TBL] [Abstract][Full Text] [Related]
2. Point mutations of the mTOR-RHEB pathway in renal cell carcinoma.
Ghosh AP; Marshall CB; Coric T; Shim EH; Kirkman R; Ballestas ME; Ikura M; Bjornsti MA; Sudarshan S
Oncotarget; 2015 Jul; 6(20):17895-910. PubMed ID: 26255626
[TBL] [Abstract][Full Text] [Related]
3. LKB1 mutations and their correlation with LKB1 and Rheb expression in bladder cancer.
Tigli H; Seven D; Tunc M; Sanli O; Basaran S; Ulutin T; Buyru N
Mol Carcinog; 2013 Aug; 52(8):660-5. PubMed ID: 22457270
[TBL] [Abstract][Full Text] [Related]
4. Underexpression of tumour suppressor LKB1 in clear cell renal cell carcinoma is common and confers growth advantage in vitro and in vivo.
Duivenvoorden WC; Beatty LK; Lhotak S; Hill B; Mak I; Paulin G; Gallino D; Popovic S; Austin RC; Pinthus JH
Br J Cancer; 2013 Feb; 108(2):327-33. PubMed ID: 23322200
[TBL] [Abstract][Full Text] [Related]
5. mTOR and mTOR phosphorylation status in primary and metastatic renal cell carcinoma tissue: differential expression and clinical relevance.
Rausch S; Schollenberger D; Hennenlotter J; Stühler V; Kruck S; Stenzl A; Bedke J
J Cancer Res Clin Oncol; 2019 Jan; 145(1):153-163. PubMed ID: 30368665
[TBL] [Abstract][Full Text] [Related]
6. Naa20, the catalytic subunit of NatB complex, contributes to hepatocellular carcinoma by regulating the LKB1-AMPK-mTOR axis.
Jung TY; Ryu JE; Jang MM; Lee SY; Jin GR; Kim CW; Lee CY; Kim H; Kim E; Park S; Lee S; Lee C; Kim W; Kim T; Lee SY; Ju BG; Kim HS
Exp Mol Med; 2020 Nov; 52(11):1831-1844. PubMed ID: 33219302
[TBL] [Abstract][Full Text] [Related]
7. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas.
Na X; Wu G; Ryan CK; Schoen SR; di'Santagnese PA; Messing EM
J Urol; 2003 Aug; 170(2 Pt 1):588-92. PubMed ID: 12853836
[TBL] [Abstract][Full Text] [Related]
8. PI3K/Akt/mTOR signaling & its regulator tumour suppressor genes
Makker A; Goel MM; Mahdi AA; Bhatia V; Das V; Agarwal A; Pandey A
Indian J Med Res; 2016 May; 143(Supplement):S112-S119. PubMed ID: 27748285
[TBL] [Abstract][Full Text] [Related]
9. Honokiol activates AMP-activated protein kinase in breast cancer cells via an LKB1-dependent pathway and inhibits breast carcinogenesis.
Nagalingam A; Arbiser JL; Bonner MY; Saxena NK; Sharma D
Breast Cancer Res; 2012 Feb; 14(1):R35. PubMed ID: 22353783
[TBL] [Abstract][Full Text] [Related]
10. Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice.
Huang X; Wullschleger S; Shpiro N; McGuire VA; Sakamoto K; Woods YL; McBurnie W; Fleming S; Alessi DR
Biochem J; 2008 Jun; 412(2):211-21. PubMed ID: 18387000
[TBL] [Abstract][Full Text] [Related]
11. Synergistic roles of p53 and HIF1α in human renal cell carcinoma-cell apoptosis responding to the inhibition of mTOR and MDM2 signaling pathways.
Liu QJ; Shen HL; Lin J; Xu XH; Ji ZG; Han X; Shang DH; Yang PQ
Drug Des Devel Ther; 2016; 10():745-55. PubMed ID: 26937175
[TBL] [Abstract][Full Text] [Related]
12. miRNA‑205‑5p functions as a tumor suppressor by negatively regulating VEGFA and PI3K/Akt/mTOR signaling in renal carcinoma cells.
Huang J; Wang X; Wen G; Ren Y
Oncol Rep; 2019 Nov; 42(5):1677-1688. PubMed ID: 31545453
[TBL] [Abstract][Full Text] [Related]
13. The mammalian target of rapamycin pathway is widely activated without PTEN deletion in renal cell carcinoma metastases.
Abou Youssif T; Fahmy MA; Koumakpayi IH; Ayala F; Al Marzooqi S; Chen G; Tamboli P; Squire J; Tanguay S; Sircar K
Cancer; 2011 Jan; 117(2):290-300. PubMed ID: 20830770
[TBL] [Abstract][Full Text] [Related]
14. Selenoprotein M stimulates the proliferative and metastatic capacities of renal cell carcinoma through activating the PI3K/AKT/mTOR pathway.
Jiang H; Shi QQ; Ge LY; Zhuang QF; Xue D; Xu HY; He XZ
Cancer Med; 2019 Aug; 8(10):4836-4844. PubMed ID: 31274247
[TBL] [Abstract][Full Text] [Related]
15. Role of AMPK/mTOR-independent autophagy in clear cell renal cell carcinoma.
Radovanovic M; Vidicevic S; Tasic J; Tomonjic N; Stanojevic Z; Nikic P; Vuksanovic A; Dzamic Z; Bumbasirevic U; Isakovic A; Trajkovic V
J Investig Med; 2020 Dec; 68(8):1386-1393. PubMed ID: 33087428
[TBL] [Abstract][Full Text] [Related]
16. The Effect of LKB1 Activity on the Sensitivity to PI3K/mTOR Inhibition in Non-Small Cell Lung Cancer.
Shukuya T; Yamada T; Koenig MJ; Xu J; Okimoto T; Li F; Amann JM; Carbone DP
J Thorac Oncol; 2019 Jun; 14(6):1061-1076. PubMed ID: 30825612
[TBL] [Abstract][Full Text] [Related]
17. Altered LKB1/AMPK/TSC1/TSC2/mTOR signaling causes disruption of Sertoli cell polarity and spermatogenesis.
Tanwar PS; Kaneko-Tarui T; Zhang L; Teixeira JM
Hum Mol Genet; 2012 Oct; 21(20):4394-405. PubMed ID: 22791749
[TBL] [Abstract][Full Text] [Related]
18. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy.
Pantuck AJ; Seligson DB; Klatte T; Yu H; Leppert JT; Moore L; O'Toole T; Gibbons J; Belldegrun AS; Figlin RA
Cancer; 2007 Jun; 109(11):2257-67. PubMed ID: 17440983
[TBL] [Abstract][Full Text] [Related]
19. Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin.
Xu J; Pham CG; Albanese SK; Dong Y; Oyama T; Lee CH; Rodrik-Outmezguine V; Yao Z; Han S; Chen D; Parton DL; Chodera JD; Rosen N; Cheng EH; Hsieh JJ
J Clin Invest; 2016 Sep; 126(9):3526-40. PubMed ID: 27482884
[TBL] [Abstract][Full Text] [Related]
20. Thymoquinone inhibits metastatic phenotype and epithelial‑mesenchymal transition in renal cell carcinoma by regulating the LKB1/AMPK signaling pathway.
Kou B; Kou Q; Ma B; Zhang J; Sun B; Yang Y; Li J; Zhou J; Liu W
Oncol Rep; 2018 Sep; 40(3):1443-1450. PubMed ID: 29956793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
